Ipsen S.A. (OTCMKTS:IPSEY – Get Free Report) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $30.55 and traded as high as $31.66. Ipsen shares last traded at $31.27, with a volume of 9,037 shares.
Analysts Set New Price Targets
Separately, Royal Bank of Canada upgraded Ipsen from a “hold” rating to a “moderate buy” rating in a report on Monday, September 16th.
Read Our Latest Stock Report on Ipsen
Ipsen Trading Up 0.1 %
About Ipsen
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
See Also
- Five stocks we like better than Ipsen
- Stock Market Upgrades: What Are They?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.